
Ixo et al. in €7.3m round for Antabio
A number of French investors including Ixo Private Equity and Galia Gestion have taken part in a €7.3m round for biotechnology company Antabio.
The series-A round included investments from Ixo, Irdi Soridec Gestion, Galia Gestion and the company's previous investors.
The fresh funding has been earmarked to advance Antabio's programmes into clinical studies, accelerating the development of the company's attempt to treat infections caused by pathogens.
Antabio was previously financed through a number of non-dilutive grants.
Company
Antabio is a French biopharmaceutical company developing antibacterial treatments, aiming to fill a gap in the treatment of drug-resistant infections.
Advisers
Equity – Chammas et Marcheteau, Antonin Cubertafond, Romain Penloup (legal).
Company – McDermott Will & Emery, Anthony Paronneau, Laetitia De Dinechin, Chloé Huertas (legal).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater